Avid Bioservices Inc (CDMO)

[entdoc]

freethemice
Agreed.And thanks for all your "inside" scientific observations here throughout the years. observations from the point of vieIn these two preclinical breastConsistently on the mark. And how about the April 2010 report of tumor studies conducted at the University of Missouri-Columbia, where a bavituximab-equivalent antibody 2aG4 was used in combination with PRIMA-1, a small molecule investigational drug that targets abnormal p53, a protein present in half of all breast cancer cases--one that suppresses apoptosis, or normal cell death. Among its multiple anti-tumor effects, PRIMA-1 increases tumor cell apoptosis which in turn exposes PS, the target for Peregrine's antibodies.
Results of that study showed the combination therapy was more effective than either treatment alone at reducing the tumor growth rate and the incidence of lymph node metastasis in two different breast tumor models. In one model 30% of all tumors were completely eradicated following combination therapy, compared to none in the control group animals. As you said, IFN-gamma, antibody-IL-2, and even TTF-like small molecules are waiting to hitch a ride on fully humanized missile Bavituximab.